Merit Medical Systems (MMSI) Projected to Post Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI) will likely be announcing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Merit Medical Systems to announce earnings of $0.96 per share and revenue of $405.2450 million for the quarter. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.10. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. During the same period in the previous year, the company posted $0.86 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. On average, analysts expect Merit Medical Systems to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Merit Medical Systems Stock Performance

Shares of Merit Medical Systems stock opened at $73.11 on Thursday. The business has a 50-day simple moving average of $67.72 and a 200 day simple moving average of $72.21. Merit Medical Systems has a one year low of $59.74 and a one year high of $94.75. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. The firm has a market capitalization of $4.36 billion, a price-to-earnings ratio of 31.65, a PEG ratio of 2.29 and a beta of 0.52.

Insider Activity at Merit Medical Systems

In related news, insider Brian G. Lloyd bought 2,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were bought at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the transaction, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director directly owned 7,809 shares in the company, valued at approximately $488,921.49. The trade was a 39.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Several large investors have recently bought and sold shares of MMSI. Los Angeles Capital Management LLC purchased a new position in Merit Medical Systems during the 4th quarter worth $25,000. Danske Bank A S purchased a new stake in shares of Merit Medical Systems in the third quarter valued at about $42,000. Quarry LP raised its holdings in shares of Merit Medical Systems by 185.9% in the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after purchasing an additional 342 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Merit Medical Systems by 973.6% during the fourth quarter. Global Retirement Partners LLC now owns 569 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 516 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Merit Medical Systems during the fourth quarter valued at about $82,000. 99.66% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MMSI has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Needham & Company LLC reduced their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Canaccord Genuity Group decreased their price target on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a report on Monday, April 20th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus target price of $92.80.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.